TABLE 3.
Comparison of survival periods in relation to genomic changes in HBV and clinical characteristics
| Variable | Univariate analysis P |
Multivariate analysis P |
HR (95 % CI) |
|---|---|---|---|
| Genomic changes | |||
| BCP, wild type/mutant | 0.876 | – | – |
| Precore, wild type/mutant | 0.442 | – | – |
| X C1653T, wild type/mutant | 0.665 | – | – |
| X T1753V, wild type/mutant | 0.331 | – | – |
| Pre-S2, wild type/deletion | 0.228 | – | – |
| Clinical characteristics | |||
| Age ≤40 y | 0.015 | 0.113 | 0.467 (0.182–1.196) |
| Male | 0.209 | – | – |
| Serum AFP > 200 ng/mL | 0.012 | 0.228 | 1.549 (0.760–3.157) |
| Serum ALT > 80 IU/L | 0.027 | 0.089 | 2.165 (0.889–5.268) |
| Serum creatinine > 1.4 mg/dL | 0.003 | 0.001 | 8.711 (2.172–34.933) |
| Child-Pugh class B or C | 0.038 | 0.085 | 2.175 (0.900–5.259) |
| Tumor characteristics | |||
| Size >5 cm | 0.004 | 0.047 | 1.976 (1.010–3.866) |
| Infiltrative type | 0.083 | 0.032 | 5.110 (1.156–22.602) |
| Microvascular invasion | <0.001 | <0.001 | 6.118 (2.986–12.535) |
| Advanced CLIP stage | 0.029 | 0.528 | 0.755 (0.351–1.711) |
HBV hepatitis B virus, HR hazard ratio, CI confidence interval, BCP basal core promoter, AFP α-fetoprotein, ALT alanine aminotransferase, CLIP Cancer of the Liver Italian Program